Chairpersons:
Kathryn
Wood, Oxford, UK
| 8:30
- 8:35 | WELCOME
AND INTRODUCTIONS
Kathryn Wood Oxford,
UK | | 8:35 - 8:55 |
MECHANISMS OF ACTION OF MYCOPHENOLATE MOFETILIN CHRONIC REJECTION
Anthony
Allison Belmont, USA | | 8:55
- 9:15 | CONTROL OF ALLOANTIBODY PRODUCTION WITH MYCOPHENOLATE
MOFETIL AND TACROLIMUS AFTER RENAL TRANSPLANTATION
Manuel
Pascual Boston, USA | | 9:15
- 9:35 | ANTI-VIMENTIN ANTIBODIES AFTER HEART TRANSPLANTATION
AND THEIR ROLE IN TRANSPLANT-ASSOCIATED CORONARY ARTERY DISEASE
Marlene
Rose Harefield, UK | | 9:35
- 9:55 | FIBROSIS IN CHRONIC REJECTION, ITS PATHOGENESIS
AND PONTENTIAL
PHARMACOLOGICAL CONTROL
Elsie
M. Eugui Palo Alto, USA | | 9:55
- 10:00 | SUMMARY AND CLOSE
Kathryn
Wood Oxford, UK | | 10:00
- 10:30 | COFFEE BREAK |
Chairpersons:
Philip F Halloran, Edmonton, Canada
Jean F Bach, Paris, France
|
10:30
- 11:00 |
WHAT DO WE
LEARN FROM PRECLINICAL MODELS?
Stuart J. Knechtle John H. Fechner Yinchen Dong Huaizhong Hu Majed M. Hamawy Madison, USA
|
|
11:00 - 11:30
|
NEW DEVELOPMENTS
IN IMMUNOSUPPRESSION
Randall E. Morris
Stanford, USA |
|
11:30
- 12:00 |
PREVENTION AND CURE OF AUTOIMMUNE DISEASES : ACHIEVABLE DREAMS?
Jean Bach Paris, France |
|
12:00 - 12:30
|
HOW TO
PREVENT LONG-TERM ALLOGRAFT DAMAGE
Phillip F. Halloran
Edmonton, Canada |
|
12:30 - 13:00
|
TAILORED IMMUNOSUPPRESSION : THE WAY
WE SHOULD FOLLOW
Paul Mohacsi Bern, Switzerland
|
|
13:00
- 13:30 |
TAILORED
IMMUNOSUPPRESSION
Ronald D. Guttmann
Montreal, Canada |
|
13:30
- 13:40 |
CLOSING REMARKS
Michael Goldman (President), Brussels, Belgium
President Elect |
| 13:30 |
FAREWELL RECEPTION - SPONSORED BY ROCHE |
|
